Last reviewed · How we verify

NCT06056258

A Study to Evaluate the Efficacy of VL-NL-02 on Sleep Quality.

Completed NA Last updated 28 January 2025
What this trial tests

NA trial testing VL-NL-02 in Mood and Sleep Quality in 48 participants. Completed in 1 April 2024.

Timeline
4 December 2023
Primary endpoint
1 April 2024
1 April 2024

Quick facts

Lead sponsorVedic Lifesciences Pvt. Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment48
Start date4 December 2023
Primary completion1 April 2024
Estimated completion1 April 2024
Sites5 locations across India

Drugs / interventions tested

Conditions studied

Sponsor

Vedic Lifesciences Pvt. Ltd. — full company profile →

Who can join

Adults 18 to 50, any sex, with Mood and Sleep Quality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to study the impact of VL-NL-02 in improving sleep quality, restorative sleep complaints, quality of life, stress levels, and sleep stages. 48 participants are expected to be randomized in a ratio of 1:1 to receive either VL-NL-02 or placebo and will be assigned a unique randomization code. Each group will have at least 20 completed participants after accounting for a dropout/withdrawal rate of 17%. The intervention duration for all the study participants is 21 days. Participants will be asked to fill multiple questionnaires to assess sleep quality and mood imbalance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Vedic Lifesciences Pvt. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06056258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing